In vitro characterization of recombinant factor VIII concentrates reveals significant differences in protein content, activity and thrombin activation profile

Haemophilia

Volumn 19, Issue 3, 2013, Pages 392-398

  Pahl, S ^a   Pavlova, A ^a   Driesen, J ^a   Muller J ^a   Potzsch B ^a   Oldenburg, J ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

FVIII activity; FVIII antigen; Recombinant FVIII concentrates; Thrombin activation

Indexed keywords

ANTIGEN; BLOOD CLOTTING FACTOR 8 CONCENTRATE; RECOMBINANT BLOOD CLOTTING FACTOR 8; THROMBIN;

ANTICOAGULATION; ARTICLE; CHROMOGENIC ASSAY; DRUG POTENCY; IN VITRO STUDY; ONE STAGE CLOTTING ASSAY; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROCEDURES; PROTEIN CONTENT; PROTEIN DOMAIN;

BLOTTING, WESTERN; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ENZYME ASSAYS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FACTOR VIII; FACTOR XA; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; THROMBIN;

EID: 84876785042     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12076     Document Type: Article

References (24)

1. Eaton DL, Wood WI, Eaton D et al. Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule. Biochemistry 1986; 25: 8343-7.
2. Gitschier J, Wood WI, Goralka TM et al. Characterization of the human factor VIII gene. Nature 1984; 312: 326-30.
3. Toole JJ, Knopf JL, Wozney JM et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312: 342-7.
4. Gruppo RA, Brown D, Wilkes MM, Navickis RJ. Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis-a meta-analysis. Haemophilia 2003; 9: 251-60.
5. Boedeker BG. The manufacturing of the recombinant factor VIII. Kogenate. Transfus Med Rev 1992; 6: 256-60.
6. Jiang R, Monroe T, McRogers R, Larson PJ. Manufacturing challenges in the commercial production of recombinant coagulation factor VIII. Haemophilia 2002; 8(Suppl. 2): 1-5.
7. Adamson R. Design and operation of a recombinant mammalian cell manufacturing process for rFVIII. Ann Hematol 1994; 68(Suppl. 3): S9-14.
8. Kelley B, Jankowski M, Booth J. An improved manufacturing process for Xyntha/ReFacto AF. Haemophilia 2010; 16: 717-25.
9. Eriksson RK, Fenge C, Lindner-Olsson E et al. The manufacturing process for B-domain deleted recombinant factor VIII. Semin Hematol 2001; 38: 24-31.
10. EMA. Advate: European public assessment report- product information, 2009.
11. EMA. Kogenate Bayer: European public assessment report- product information, 2009.
12. Rosen S, Casoni MC. Determination of factor VIII activity in plasma and concentrates: comparison between methods. Am Clin Lab 2002; 21: 32-7.
13. EMA. ReFacto AF: European public assessment report- product information, 2009.
14. Barrowcliffe TW, Raut S, Sands D, Hubbard AR. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations. Semin Thromb Hemost 2002; 28: 247-56.
15. Butenas S, Parhami-Seren B, Gissel MT, Gomperts ED, Fass DN, Mann KG. Potency and mass of factor VIII in FVIII products. Haemophilia 2009; 15: 63-72.
16. Barrowcliffe TW, Hubbard AR, Kitchen S. Standards and monitoring treatment. Haemophilia 2012; 18(Suppl. 4): 61-5.
17. Jankowski MA, Patel H, Rouse JC, Marzilli LA, Weston SB, Sharpe PJ. Defining 'full-length' recombinant factor VIII: a comparative structural analysis. Haemophilia 2007; 13: 30-7.
18. Grancha S, Navajas R, Maranon C, Paradela A, Albar JP, Jorquera JI. Incomplete tyrosine 1680 sulphation in recombinant FVIII concentrates. Haemophilia 2011; 17: 709-10.
19. Michnick DA, Pittman DD, Wise RJ, Kaufman RJ. Identification of individual tyrosine sulfation sites within factor VIII required for optimal activity and efficient thrombin cleavage. J Biol Chem 1994; 269: 20095-102.
20. Shapiro AD. Anti-hemophilic factor (recombinant), plasma/albumin-free method (octocog-alpha; ADVATE) in the management of hemophilia A. Vasc Health Risk Manag 2007; 3: 555-65.
21. Bowyer AE, Goodeve A, Liesner R, Mumford AD, Kitchen S, Makris M. p.Tyr365Cys change in factor VIII: haemophilia A, but not as we know it. Br J Haematol 2011; 154: 618-25.
22. Oldenburg J, Pavlova A. Discrepancy between one-stage and chromogenic factor VIII activity assay results can lead to misdiagnosis of haemophilia A phenotype. Hamostaseologie 2010; 30: 207-11.
23. Sandberg H, Almstedt A, Brandt J et al. Structural and functional characteristics of the B-domain-deleted recombinant factor VIII protein, r-VIII SQ. Thromb Haemost 2001; 85: 93-100.
24. Schaub RG. Recent advances in the development of coagulation factors and procoagulants for the treatment of hemophilia. Biochem Pharmacol 2011; 82: 91-8.